Doctors and health experts have officially renamed PCOS to better reflect the full impact of the condition on women’s health.
Polycystic Ovary Syndrome (PCOS), one of the most common hormonal disorders affecting women, has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS).
The name change was announced in a global consensus published in The Lancet, with support from more than 50 medical and patient organisations and feedback from over 14,000 women living with the condition.
Experts said the old name “PCOS” was misleading because ovarian cysts are not the main feature of the disorder. The new name highlights how the condition affects hormones, metabolism and ovarian function.
PMOS can cause irregular periods, acne, excess body hair, fertility challenges and higher risks of Type 2 diabetes and heart disease. Health experts estimate that between five and six million women in the United States live with the condition, while many cases remain undiagnosed.
Doctors also say women with PMOS can still become pregnant with proper treatment and reproductive support. Lifestyle changes, medication and hormone management remain key parts of treatment.
The condition affects women across all racial groups, but studies suggest Black and Hispanic women often face more severe complications and delayed diagnosis.
Medical experts say the new PMOS name could improve awareness, reduce stigma and help more women receive earlier diagnosis and treatment.